| Vaccine | Trade Name | Abbreviation | Manufacturer | Doses in Routine Series | Approved Ages | Comments | |
|---|---|---|---|---|---|---|---|
| DT | Generic | DT | sanofi | IM 5 |
6 weeks-6 years | Inactivated, Adj.: Use when pertussis is contraindicated | |
| Hepatitis A | Havrix® | HepA | GlaxoSmithKline | IM 2 |
Pediatric: 12 months-18 years Adult: ≥19 years |
Inactivated, Adj. | |
| Vaqta® | HepA | Merck | IM 2 |
Pediatric: 12 months-18 years Adult: ≥19 years |
Inactivated, Adj. | ||
| Hepatitis B | Engerix-B® | HepB | GlaxoSmithKline | IM 3 |
Pediatric: Birth-19 years Adult: ≥20 years |
Recombinant, Adj. | |
| Recombivax HB® | HepB | Merck | IM 3 |
Pediatric: Birth-19 years Adult: ≥20 years |
Recombinant, Adj. | ||
| Heplisav-B® | HepB | Dynavax Technologies | IM 2 |
≥18 years | Recombinant, Adj. | ||
| Herpes Zoster (Shingles) | Shingrix® | RZV | GlaxoSmithKline | IM 2 |
≥50 years | Recombinant, Adj. | |
| Human Papillomavirus (HPV) |
Gardasil® 9 | 9vHPV | Merck | IM 2 or 3 |
9-45 years | Recombinant, Adj. ACIP recommends 9-26 years |
|
| Japanese encephalitis | Ixiaro® | JE | Valneva | IM 2 | ≥2 months | Inactivated, Adj. | |
| Measles, Mumps, Rubella | M-M-R® II | MMR | Merck | SC 2 | ≥12 months | Live Attenuated | |
| Pneumococcal | Pneumovax® 23 | PPSV23 | Merck | IM or SC 1 |
≥2 years | Inactivated Polysaccharide | |
| Prevnar 13® | PCV13 | Pfizer | IM 4 |
≥6 weeks | Inactivated, Adj. (CRM197 conjugate) |
||
| Polio | Ipol® | IPV | sanofi | IM or SC 4 |
≥6 weeks | Inactivated | |
| Rotavirus | RotaTeq® | RV5 | Merck | Oral (Liquid) 3 |
6-32 weeks | Live, Pentavalent | |
| Rotarix® | RV1 | GlaxoSmithKline | Oral (Liquid) 2 |
6-24 weeks | Live, Monovalent | ||
| Tetanus, (reduced) Diphtheria |
Tenivac® | Td | sanofi | IM 1 (Every 10 years) |
≥7 years | Inactivated, Adj. | |
| (Generic) | Td | Massachusetts Biological Labs | IM 1 (Every 10 years) |
≥7 years | Inactivated, Adj. | ||
| Tetanus, (reduced) Diphtheria, (reduced) Pertussis |
Boostrix® | Tdap | GlaxoSmithKline | IM 1 |
≥10 years | Inactivated, Adj. | |
| Adacel® | Tdap | sanofi | IM 1 |
10-64 years | Inactivated, Adj. | ||
| Typhoid | Typhim Vi® | sanofi | IM 1 |
≥2 years | Inactivated, Polysaccharide | ||
| Vivotif® | PaxVax | Oral (Capsules) 4 |
≥6 years | Live Attenuated | |||
| Varicella | Varivax® | VAR | Merck | SC 2 |
≥12 months | Live Attenuated | |
| Vaccinia (Smallpox) | ACAM2000® | sanofi | Percutaneous 1 |
All ages | Live Attenuated | ||
| Yellow Fever | YF-Vax® | YF | sanofi | SC 1 |
≥9 months | Live Attenuated | |
1. Tdap
• Preteens between 11-12 years of age should receive 1 dose of Tdap to help boost their immunity after receiving DTaP during their childhood. If you or someone you know has not received a Tdap vaccine by 11-12 years of age, it is recommended to get one dose at their next visit to the doctor’s office or a pharmacy.
• Tdap is also recommending for woman during every pregnancy, see more information on this below.
• Do NOT get Tdap if you are younger than 7 years of age
2. Td
• 10 years after receiving Tdap, every adult should receive a Td vaccine to keep their immunity strong! In case an adult has not received the Tdap vaccine before, they should get the
• Do NOT get Td if you are younger than 7 years of age.
3. DTaP
• Given 5 times throughout a child’s initial years at 2 months, 4 months, 6 months, 15-18 months, and 4-6 years of age.
• Do NOT get DTaP if you are 7 years of age or older.
4. DT
• Given to children who SHOULD NOT receive the whooping cough (pertussis) part of the vaccine such as an allergic reaction to DTaP.
• Do NOT get DT if you are 7 years of age or older.